Gasporox (GPX) investor relations material

Executive summary

• Achieved strong momentum in Q1 2026 with increased order intake, broader customer base, and new technological advances supporting continued growth.

• Revenue for Q1 2026 reached 8,797 KSEK, with positive EBITDA and improved operating results year-over-year.

• Main deliveries were to the pharmaceutical industry, with food sector contributing via measurement instruments and sensors.

• First sale of LineArch machine to a major European customer, marking entry into inline solutions for production lines.

• Launch of new products and technologies, including TLM method and expanded GPX3000 series, planned at Interpack trade fair.

Financial highlights

• Net revenue for Q1 2026 was 8,797 KSEK, up from 3,970 KSEK in Q1 2025.

• Operating result improved to -1,161 KSEK from -4,119 KSEK year-over-year.

• EBITDA turned positive at 523 KSEK, compared to -2,583 KSEK in Q1 2025.

• Cash flow for the quarter was 6,182 KSEK, with cash and equivalents at 12,833 KSEK at period end.

• Earnings per share before dilution was -0.17 SEK, improved from -0.49 SEK in Q1 2025.

Outlook and guidance

• Continued focus on expanding technology and customer base, with pharmaceutical industry as primary market.

• Strategy to drive profitable, scalable growth through technology development and deeper integration in production environments.

• Long-term goal to have solutions installed in 10-20% of new production lines.